US 11071727
Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
granted A61KA61K31/4375A61P
Quick answer
US patent 11071727 (Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors) held by Northwestern University expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Northwestern University
- Grant date
- Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 2
- CPC classes
- A61K, A61K31/4375, A61P, A61P35/02